source
- Verastem’s experimental KRAS drug shows early promise in small study, shares jump 18%Verastem Oncology announced early data from a small study of its experimental drug VS-7375, which targets the KRAS G12D mutation. The study enrolled patients with metastatic pancreatic ductal aden…
- Roche signs $1 billion deal with China’s Rona Therapeutics for RNAi obesity drugRoche announced a new agreement with Chinese biotech Rona Therapeutics to acquire an experimental RNA interference therapy targeting the protein ALK7 for obesity. Under the terms, Roche will pay $…